Structure-based discovery of nonhallucinogenic psychedelic analogs
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Drugs that target the human serotonin 2A receptor (5-HT 2A R) are used to treat neuropsychiatric diseases; however, many have hallucinogenic effects, hampering their use. Here, we present structures of 5-HT 2A R complexed with the psychedelic drugs psilocin (the active metabolite of psilocybin) and d -lysergic acid diethylamide (LSD), as well as the endogenous neurotransmitter serotonin and the nonhallucinogenic psychedelic analog lisuride. Serotonin and psilocin display a second binding mode in addition to the canonical mode, which enabled the design of the psychedelic IHCH-7113 (a substructure of antipsychotic lumateperone) and several 5-HT 2A R β-arrestin–biased agonists that displayed antidepressant-like activity in mice but without hallucinogenic effects. The 5-HT 2A R complex structures presented herein and the resulting insights provide a solid foundation for the structure-based design of safe and effective nonhallucinogenic psychedelic analogs with therapeutic effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, to target 5-HT 2A R, the combination of LSD and psilocybin can lead to biased activation of the mediated signaling pathway and produce antidepressant effects without the side effects of hallucinations. 387”
From Major depressive disorder: hypothesis, mechanism, prevention and treatment (2024) · cites this paper as [387]
In the citing paper
“While LSD binds to the orthosteric site of the 5-HT 2A R, certain ergoline-like analogs of LSD bind to the 5-HT 2A R at an extended binding pocket (Cao et al., 2022).”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Cao et al., 2022
In the citing paper
“In a separate study, the psychedelic analog IHCH-7113 and several other 5-HT 2A R b -arrestin-biased agonists also demonstrate antidepressant-like activity in mice without hallucinogenic effects (Cao et al., 2022), although their dendritic and synaptic effects remain to be elucidated.”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Cao et al., 2022
Citations
Cites
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
Integration, scaling, space-group assignment and post-refinement
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047374 · Cited by 2,528
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
The expanded biology of serotonin
Berger, M., Gray, J. A., & Roth, B. L. (2009) · Annual Review of Medicine · doi:10.1146/annurev.med.60.042307.110802 · Cited by 2,100
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Trial of Psilocybin versus Escitalopram for Depression
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032994 · Cited by 1,391
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
Operational models of pharmacological agonism
Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society of London. Series B. Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 951
Research works printed but not linked: 3
- A. S. A. T. Shulgin PIHKAL: A Chemical Love Story (Transform Press 1991).
- A. S. A. T. Shulgin TIHKAL: The Continuation (Transform Press 1997).
- 10.1073/pnas.0708862105 · DOI · Paper page
Cited by
Items 201–300 of 314
Jensen, A. A., Cecchi, C. R., Hibicke, M., Bach, A. H., Kaadt, E., Märcher-Rørsted, E., Nichols, C. D., Elfving, B., & Kristensen, J. L. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00208 · Cited by 4
Designing nonhallucinogenic psychedelic analogues
Crunkhorn, S. (2022) · Nature Reviews Drug Discovery · doi:10.1038/d41573-022-00027-z · Cited by 4
Making Sense of Psychedelics in the CNS
Fordyce, B. A., & Roth, B. L. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae007 · Cited by 4
Chemoselective synthesis of tertiary and secondary amines by reductive amination of aldehydes
Xiong, W.-J., Li, L., Li, J., Zhang, S., Tang, J., & Zhou, T. (2023) · Tetrahedron Letters · doi:10.1016/j.tetlet.2023.154684 · Cited by 3
Self-citationTavares, V. D. D. O., Gonçalves, K. T. D. C., Barros, M. L. D. M., de Brito, A. J. C., Cavalcanti-Ribeiro, P., Palhano-Fontes, F., Falchi-Carvalho, M., Nunes, E. A., Sarris, J. J., Perkins, D., et al. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001946 · Cited by 5
Post-translational modifications orchestrate the intrinsic signaling bias of GPR52
Zhang, B., Ge, W., Ma, M., Li, S., Yu, J., Yang, G., Wang, H., Li, J., Li, Q., Zeng, R., et al. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01864-w · Cited by 7
Self-citationDu, X., Liu, J., & Wang, X. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03291-8 · Cited by 4
Meaning and Psychedelics in Palliative Care: A Narrative Review
Alexander, W. B., Hansen, E., Anderson, B. T., Zarrabi, A. J., Rogers, A. H., Loewen, G., Ficcaro, Z. R., Alexander, M. H., Schaefer, D., & Case, A. A. (2025) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2025.10.015 · Cited by 4
Lu, D., Ruan, Y., Zhou, F., Ma, Y., Chang, J., Wei, Y., Xu, R., Wang, J., & Shen, X. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03581-6 · Cited by 3
Barker, S. A. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00695 · Cited by 3
Rudin, D., Ren, X., Liechti, M. E., Huang, N., & Arias, H. R. (2026) · Neurochemical Research · doi:10.1007/s11064-026-04727-5 · Cited by 3
Rational design of Gi-biased CB1 agonist with reduced side effects
Liao, Y.-Y., Che, J., Yun-tao, G., Xue, J., Li, L., Wu, L.-L., Hu, J.-X., Hu, M.-T., Xie, L., Zhang, H., et al. (2026) · Cell · doi:10.1016/j.cell.2026.03.020 · Cited by 3
Self-citationComputational Methods for the Discovery and Optimization of TAAR1 and TAAR5 Ligands
Scarano, N., Espinoza, S., Brullo, C., & Cichero, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158226 · Cited by 3
Taking the tripping out of psychedelic medicine
Dolgin, E. (2022) · Nature · doi:10.1038/d41586-022-02869-4 · Cited by 3
Chruścicka‐Smaga, B., Machaczka, A., Szewczyk, B., & Pilc, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00547-4 · Cited by 5
α-Ethyltryptamine: A Ratiocinatory Review of a Forgotten Antidepressant
Glennon, R. A., & Dukat, M. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00139 · Cited by 3
Hilal, F. F., Jeanblanc, J., & Naassïla, M. (2023) · Biologie Aujourd hui · doi:10.1051/jbio/2023028 · Cited by 4
Zięba, A., Bartuzi, D., Stępnicki, P., Matosiuk, D., Wróbel, T. M., Laitinen, T., Castro, M., & Kaczor, A. A. (2024) · ChemMedChem · doi:10.1002/cmdc.202400080 · Cited by 3
de Miranda, A. S., Toscano, E. C. D. B., Venna, V. R., Graeff, F. G., & Teixeira, A. L. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2460674 · Cited by 4
The Promise of Psychedelic Research
Peritore, C. (2022) · Future Drug Discovery · doi:10.4155/fdd-2021-0012 · Cited by 3
Design and synthesis of beta-Arrestin-biased 5HT2AR agonists
D’Andrea, L. (2023) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau528157052 · Cited by 6
Abboud, A. E., Schiebrel, C. M., Nahhas, R. W., Durkin, S., Hua, K., Redding, H., & Gainer, D. M. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2511752 · Cited by 2
Stirn, J., Berger, R., Hübner, H., Gmeiner, P., & Klein, C. D. P. (2025) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2025.100278 · Cited by 2
Palmisano, V. F., Agnorelli, C., Faraji, S., & Nogueira, J. J. (2025) · Physical Chemistry Chemical Physics · doi:10.1039/d5cp01252j · Cited by 2
Molecular dynamics study of differential effects of serotonin-2A-receptor (5-HT2AR) modulators
Peeters, J., Bundel, D. D., & Vanommeslaeghe, K. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013000 · Cited by 2
Tariq, S., Qureshi, U., Mushtaq, M., Munsif, S., Nur‐e‐Alam, M., Hawwal, M. F., Wang, Y., & Ul‐Haq, Z. (2025) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.70055 · Cited by 2
Li, R., Yan, H., Chen, Y., Liu, Y., Tang, L., Yu, J., Liu, J., Wang, H., Wang, S., & Cheng, J. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02045 · Cited by 3
Self-citationMiranda-Azpiazu, P., Muguruza, C., Stępniewski, T. M., Arrate, I. M., Moreira, D., Brea, J. M., Callado, L. F., Loza, M. I., González‐Maeso, J., Selent, J., et al. (2025) · Molecular Pharmacology · doi:10.1016/j.molpha.2025.100075 · Cited by 3
Luethi, D., Glatfelter, G. C., Pottie, E., Sellitti, F., Maitland, A. D., Gonzalez, N. R., Kryszak, L. A., Jackson, S. N., Hoener, M. C., Stove, C. P., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03325-1 · Cited by 4
AI-MedCraft: A Strategy-Driven AI Platform for Multi-Objective Molecular Design
Barakat, K., Ruiz, M. J. R., Ahmed, H. R., Shahini, E., & Barakat, Y. (2026) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6c00329 · Cited by 2
Glatfelter, G. C., Schalk, S. S., Walther, D. M., Maitland, A. D., Gonzalez, N. R., Partilla, J. S., Anas, N. A., Chadeayne, A. R., Naeem, M., Manke, D. R., et al. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00083 · Cited by 3
Deng, Y., Wang, S., Geng, L., Meng, Z., Chen, F., Yang, X., Wang, F., Chen, Y., Li, Z., & Xie, Z. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00858 · Cited by 2
Self-citationGPCR Biased Signaling: Conceptual Advancements and Therapeutic Innovation
Li, S., Huang, Y., Sun, X., & Shen, A. (2026) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2026.100011 · Cited by 2
Li, H.-J., Xiao, Y., Liu, X., Chen, X. G., Xu, J., Chen, J. L., Cheng, T., Chung, S., Shu, Y., & Shao, Z. (2026) · BMC Medicine · doi:10.1186/s12916-026-05039-9 · Cited by 2
Self-citationRole of β-Arrestin2 Signaling in Neuropharmacological Effects of Psychedelic Drugs
Ippolito, A., Tiranti, A., Hurley, S., Gilmour, G., Churchill, G. C., & Sharp, T. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00138 · Cited by 3
Baker, J., Kogan, E., Ma, S., Lu, J., & Zuo, Y. (2026) · Nature Neuroscience · doi:10.1038/s41593-026-02490-y · Cited by 3
Psychedelic LSD activates neurotrophic signal but fails to stimulate neural stem cells
Dong, X., He, L., Li, Y., Pei, G., & Huang, S. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03909-8 · Cited by 4
Self-citationKhadanga, M., Kar, N. R., Sahoo, N., & Tripathy, B. (2024) · Digital Chinese Medicine · doi:10.1016/j.dcmed.2025.01.002 · Cited by 2
The Ethics of Set and Setting in Psychedelic Psychotherapy
Patch, K., & Smith, W. (2025) · Neuroethics · doi:10.1007/s12152-025-09600-w · Cited by 2
Contribution of serotonin 5-HT2A receptor to antidepressant effect of serotonergic psychedelics
Ibi, D. (2023) · Folia Pharmacologica Japonica · doi:10.1254/fpj.22141 · Cited by 2
Kamdar, J. H., Kumari, D., & Kapadiya, K. M. (2023) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557523666230508162439 · Cited by 2
Qin, W., Zhang, B., Wang, Q., Jiang, G., Cui, J., Chen, F., Wang, L., Chen, J., Tian, S., Zhen, X.-C., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02115 · Cited by 1
Sobańska, A. W., Sobański, A. M., & Brzezińska, E. (2026) · Molecules · doi:10.3390/molecules31020212 · Cited by 1
Allosteric activation of the glutamate receptor mGlu2 by the serotonin receptor 5-HT2A
Gai, S., Lin, L., Meng, J., Wu, Y., Li, X., Xu, C., Sun, Q., Ricarte, A., Dalton, J. A. R., Renault, P., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-69939-3 · Cited by 3
Quo Vadis translational neuroscience?
Dere, E. (2026) · Translational Neuroscience · doi:10.1515/tnsci-2025-0393 · Cited by 1
Psychedelic therapy and postpartum depression: priorities and prospects
Thuery, G., Crossen, F., McLoone, D., Hinds, C., Duffy, R. T., Jairaj, C., Harkin, A., & Kelly, J. R. (2026) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253251408280 · Cited by 1
Zhang, C., Jiang, P., Wang, Y., & Wang, X. (2026) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2026.2649897 · Cited by 1
Pottie, E., Vertriest, E., Martínez-Afani, D., Soares, B. A., Cassels, B. K., & Stove, C. P. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00352 · Cited by 1
Zhang, Q.-X., Zhang, Y.-X., Jiang, C.-C., Cheng, J.-W., Tao, S.-J., Pan, Y., Kohji, F., Chen, S.-Y., Mao, X., Zhang, L., et al. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02651-2 · Cited by 2
Self-citationSynthesis of Clausenamide Isomers and Evaluation of Their Potential as Cortical Neuroplastogens
Ou, Y., Khatib, Y. A., Mosswood, A., Roy, T. K., Gutierrez, D. A., Olson, D. E., & Shaw, J. T. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00767 · Cited by 1
Potoczna, M., Kasica, N., Chmielewska-Krzesińska, M., Dybalska-Szczepanek, J., Wa̧sowicz, K., Sokołowska, E., & Podlasz, P. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119680 · Cited by 1
Ezeaka, U. C., Kim, H. J. J., & Laprairie, R. B. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230705151922 · Cited by 2
THE SEROTONIN 5-HT 2A RECEPTOR AS AN EVOLVING NEUROTHERAPEUTIC TARGET
Bolinger, A. A., Anastasio, N. C., Cunningham, K. A., & Zhou, J. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch03 · Cited by 1
Kordylewski, S. K., Bugno, R., Bojarski, A. J., & Podlewska, S. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00622-4 · Cited by 1
Exploring the Potential of Coumarin Derivatives on Serotonin Receptors 5-HT1A and 5HT2A
Ostrowska, K., Horosz, G., Kruk, K., Sieroń, B., Leśniak, A., Czartoryska, Z., Bujalska‐Zadrożny, M., Milenković, D., & Trzaskowski, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051946 · Cited by 1
Discovery of Rapid-Acting, Orally Available Antidepressants by Activating TrkB Signaling
Cheng, X., Jiang, F., Liu, L., Wang, Y., Chen, S., & Cui, W. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01750 · Cited by 1
Palmisano, V. F., Agnorelli, C., Erritzøe, D., Fagiolini, A. M., Faraji, S., & Nogueira, J. J. (2023) · ChemRxiv · doi:10.26434/chemrxiv-2023-0jwg5 · Cited by 1
Xiang, X., Qian, C., Yao, H., Li, P., Cheng, B., Wei, D., An, W., Lu, Y., Chu, M., Wei, L., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.21.529454 · Cited by 1
Self-citationCall for Papers for a Virtual Special Issue on GPCR Signaling
Ballet, S. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00036
Fu, Y., Zhu, Y., Zhang, Y., & Hu, S. (2022) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2022.103305
Han, Y. M., TangSheng, L. U., & Lü, L. T. (2023) · Scientia Sinica Vitae · doi:10.1360/ssv-2023-0049
Prediction of TrkB Complex and Antidepressant Targets Leveraging Big Data
Xiang, X., Qian, C., Liu, X., & Xia, F. (2023) · Lecture notes in computer science · doi:10.1007/978-3-031-44725-9_11
Self-citationCrystal structure and X-ray powder diffraction data for Lumateperone tosylate
Liu, J., Shi, D., Liu, S., & Hu, X.-R. (2023) · Powder Diffraction · doi:10.1017/s0885715623000337
Corrigendum to: Introduction to the chemistry and pharmacology of psychedelic drugs
Walker, S. R., Pullella, G. A., Piggott, M., & Duggan, P. J. (2024) · Australian Journal of Chemistry · doi:10.1071/ch23050_co · Cited by 3
Letzte Geheimnisse des Roten Keulenkopfs und seiner Inhaltsstoffe werden ans Licht gebracht
Petersen, F. (2024) · Springer eBooks · doi:10.1007/978-3-662-69508-1_10
CNS Biased Agonism and the Promise of Targeting Drugs Beyond Receptors to Cellular Pathways
Melnick, L. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-61992-2_9
Asrar, B., Hassam, M., Rafi, S., Ullah, I., Homberg, J. R., & Haleem, D. J. (2025) · Behavioural Brain Research · doi:10.1016/j.bbr.2025.115494
Last secrets of ergot and its ingredients are revealed
Petersen, F. (2025) · Springer eBooks · doi:10.1007/978-3-662-69811-2_10
Biological mechanisms of stress-related mental disorders
Shi, D., Wang, L., Li, X., Hu, J., Qin, S., Zhao, M., Duan, S., Wang, Y., & Wang, Z. (2025) · Scientia Sinica Vitae · doi:10.1360/ssv-2024-0346
Structural Basis of GPCR-Biased Modulation
Zhang, Y. (2025) · Handbook of experimental pharmacology · doi:10.1007/164_2025_768
To Be Biased or Not to Be: A Play for G-Protein Coupled Receptors
Liolitsas, N. G., Pantazaka, E., & Papadimitriou, Ε. (2025) · International Journal of Translational Medicine · doi:10.3390/ijtm5040056 · Cited by 1
Wang, C., Li, Y., Yi, Y., Liu, G., Guo, R., Wang, L., Lan, T., Wang, W., Chen, X., Chen, S., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21628939
Interactions and activity of lysergol derivatives at 5 HT1A and 5-HT2A–C receptors
Termonen, T. (2024) · UTUPub (University of Turku)
Meccia, J. (2023) · eScholarship@McGill (McGill) · doi:10.82308/31606
G-protein subtype selectivity in dopamine D1 receptor
Nguyen, A. M. (2025) · Digital Repository Service (Northeastern University) · doi:10.17760/d20791815
Sancilio, F. D., Dariani, M., Chavda, P., Rajagopal, H. M., & Tomlinson, L. (2026) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2607726
A structural overview of G-protein-coupled receptors in neurological disorders
Gupta, O. D., Chakraborty, I., & Pal, K. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01712-6
Scheggi, S., Braccagni, G., Branca, C., & Bortolato, M. (2026) · Aggression and Violent Behavior · doi:10.1016/j.avb.2026.102139
Palmisano, V. F., Vidal−Sánchez, M., & Nogueira, J. J. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00023
From fundamental phosphorus chemistry all the way to flow : a psychedelic journey
Simoens, A. (2025) · Ghent University Academic Bibliography (Ghent University)
Zhang, C., Li, M., Ma, J., Wang, Y., Song, Z., & Wang, X. (2026) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6c03569 · Cited by 1
Decoding the structure of GPR151 via NELiS
Wang, Y., Fan, L., Song, Q., Li, Y., Jin, J., Zhao, Q., Gu, W., Shi, X., Li, D., Cong, Y., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2534234123
Self-citationClemente, W. S., Bezerra, K. S., Matias, E. G. C., de Oliveira, J. J., & Fulco, U. L. (2026) · Physical Chemistry Chemical Physics · doi:10.1039/d6cp00943c
Enriquez‐Geppert, S., Bevers, L., Rosander, A., Fodran, P., & Polito, V. (2026) · Biomolecules · doi:10.3390/biom16070983
Ketamine-induced analgesia and dissociation show distinct behavioral and neural correlates
Goldway, N., Jalon, I., Agbaria, Y., Pasternak, Y., Sar-El, R., Mirelman, D., Sarna, N., Green, N., Hendler, T., & Sharon, H. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02496-x
Younkin, J., Bansode, A. H., Saha, S., Paymode, A., Maltman, J. L., Jones, C. B., Silverman, J. M., Buzzi, B., Jaster, A. M., Fiorillo, M., et al. (2026) · Science Signaling · doi:10.1126/scisignal.adw6055 · Cited by 1
Multidimensional characterization of the physiological and behavioral effects of TCB-2 in micePreprint
Yamamoto, M., Inoue, H., Hayashi, K., Aota, I., Matsumoto, J., Yamada, K., & Toda, K. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.01.742216
Inhalable Psychedelic 5-MeO-DMT Shows Promise in Treatment-Resistant Depression
Ali, S., Tian, X., Anastasio, N. C., Cunningham, K. A., & Zhou, J. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c02323
A signaling signature distinguishes hallucinogenic from non-hallucinogenic psychedelics
Martin-Guerrero, S. M., Taddei-Tardon, M., Maltman, J. L., Potukanuma, S., González‐Maeso, J., Cutillas, P. R., & López‐Giménez, J. F. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04390-y
Structural basis for Kisspeptin-10 selectivity toward KISS1R: computational insights
Netesa, M. A., Pyurveev, S. S., Лебедев, А. А., Бычков, Э. Р., Skorb, E. V., Shityakov, S., & Shabanov, P. D. (2026) · In Silico Pharmacology · doi:10.1007/s40203-026-00726-0
Ye, S. (2026) · In Silico Pharmacology · doi:10.1007/s40203-026-00745-x
Shinozuka, K., Dumanis, S. B., & Williams, N. (2026) · Springer eBooks · doi:10.1007/978-3-032-31497-0_6
Translational Neuroscience: Foundations for Precision Therapies
Nikolich, K., & Malenka, R. C. (2026) · Springer eBooks · doi:10.1007/978-3-032-31497-0
Li, H., & Wang, X. (2026) · Psychedelics. · doi:10.61373/pp026w.0006
Deconstruction of lysergic acid diethylamide
Basargin, A. G., Domokos, A., Hennessey, J. J., Aarrestad, I. K., Sambyal, R., Khatib, Y. A., Krüger, J., Dunlap, L. E., Carter, S. J., Rebek, I. A., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2603412123
Xia, K., Wang, Y., Liu, J., Yao, Y., 苏瑞斌, & Yan, H. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03894-9
Next-Generation Psychedelic Drug Development
Cameron, L. P., Johnson, M. W., Murnane, K. S., Rasenick, M. M., & Nichols, C. D. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6c00492
Mechanistic Basis for 5-HT2AR Over 5-HT2BR Activation
Tang, L., Ji, X., Wang, Y., Cao, D., Li, H., He, L., Cheng, J., & Wang, S. (2026) · Nature Communications · doi:10.1038/s41467-026-77659-x
Self-citation
Metadata
- Authors
- Cao, D., Yu, J., Wang, H., Luo, Z., Liu, X., He, L., Qi, J., Fan, L., Tang, L., Chen, Z., Li, J., Cheng, J., & Wang, S.
- Affiliations
- Chinese Academy of Sciences (CN)
- ShanghaiTech University (CN)
- Soochow University (CN)
- Corresponding author
- Cao, Dongmei
- Yu, Jing
- Wang, Huan
- Luo, Zhipu
- Liu, Xinyu
- Cheng, Jianjun
- Wang, Sheng
- ORCID
- Venue
- Science
- Published
- 2022-01-28
- Volume
- 375
- Issue
- 6579
- Pages
- 403-411
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W4210474529
- Cited by
- 312
- References
- 46
- Citations by year
- 2026: 50 · 2025: 77 · 2024: 84 · 2023: 69 · 2022: 32
- FWCI
- 59.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- 5-HT2A receptor, psilocin, LSD, lisuride, structure-based drug design, receptor-ligand complex, lumateperone, antidepressant-like effects, hallucinogenic effects
- MeSH terms
- Animals, Antidepressive Agents, Binding Sites, Hallucinations, Hallucinogens, Heterocyclic Compounds, 4 or More Rings, Humans, Ligands, Lisuride, Lysergic Acid Diethylamide, Protein Conformation, Psilocybin, Serotonin, Structure-Activity Relationship, Drug Design, Signal Transduction, Crystallography, X-Ray, Arrestin, Receptor, Serotonin, 5-HT2A, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.